Targeted therapy in atopic dermatitis: Endotype heterogeneity, treatment sequencing, and lessons from a contracting pipeline: A narrative review
- 1Palliative Care and Pain Management Unit, ,
- 2Department of Dermatology, Universidad de los Andes,
- 3School of Medicine, ,
Abstract
Atopic dermatitis is the most prevalent chronic inflammatory skin disease worldwide, and seven targeted systemic agents have been approved for moderate-to-severe disease since 2017. This narrative review addresses a question that the expanding evidence base has made urgent but has not resolved: given several agents of broadly comparable efficacy, how should a clinician choose between them, and what should be done when the first choice fails? We summarize the current understanding of disease mechanisms, focusing on endotype heterogeneity—intrinsic disease, T helper 17 and 22 contributions, and molecular variation across ancestral and age groups—that the dominant type 2 paradigm does not fully capture. Furthermore, we evaluated the approved biologics and oral Janus kinase inhibitors and compared the speed of response, magnitude of benefit, safety, and monitoring burden to develop an explicit framework for first-line selection, treatment sequencing after inadequate response, and long-term maintenance, including dose interval extension. We also examined a development that reframes prevailing expectations; during 2026, both agents targeting the OX40–OX40L axis were withdrawn from development in atopic dermatitis, including one that was withdrawn after a malignancy signal. Together with earlier failures of alarmin blockade, this narrows the near-term pipeline and highlights the need for better use of existing therapies. Validated predictive biomarkers remain the principal unmet need.
Related
- Vitiligo developing during dupilumab treatment in a child with atopic dermatitis: a case report and literature review
- Stapokibart (CM310) in Atopic Dermatitis: A Narrative Review of a Next-Generation IL-4Rα Antagonist.
- Long-term upadacitinib treatment in a patient with atopic dermatitis, bullous pemphigoid, and alopecia areata: a case report and review of the literature
- From Rescue Therapy to Mechanism-Based Sequencing in Refractory Myasthenia Gravis: A Narrative Review with an Illustrative Clinical Case
- Rapid whole-genome sequencing in the pediatric intensive care unit: from etiologic diagnosis to precision management—a narrative review
BibTeX
@article{davalos2026targeted,
title = {{Targeted therapy in atopic dermatitis: Endotype heterogeneity, treatment sequencing, and lessons from a contracting pipeline: A narrative review}},
author = {Maximiliano Dávalos and Fernando Valenzuela and Sebastián Celedón},
journal = {Journal of International Medical Research},
year = {2026},
month = nov,
doi = {10.1177/03000605261501668},
url = {https://doi.org/10.1177/03000605261501668},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Targeted therapy in atopic dermatitis: Endotype heterogeneity, treatment sequencing, and lessons from a contracting pipeline: A narrative review
AU - Maximiliano Dávalos
AU - Fernando Valenzuela
AU - Sebastián Celedón
PY - 2026
DA - 2026/11/02
JO - Journal of International Medical Research
DO - 10.1177/03000605261501668
UR - https://doi.org/10.1177/03000605261501668
AB - Atopic dermatitis is the most prevalent chronic inflammatory skin disease worldwide, and seven targeted systemic agents have been approved for moderate-to-severe disease since 2017. This narrative review addresses a question that the expanding evidence base has made urgent but has not resolved: given several agents of broadly comparable efficacy, how should a clinician choose between them, and what should be done when the first choice fails? We summarize the current understanding of disease mechanisms, focusing on endotype heterogeneity—intrinsic disease, T helper 17 and 22 contributions, and molecular variation across ancestral and age groups—that the dominant type 2 paradigm does not fully capture. Furthermore, we evaluated the approved biologics and oral Janus kinase inhibitors and compared the speed of response, magnitude of benefit, safety, and monitoring burden to develop an explicit framework for first-line selection, treatment sequencing after inadequate response, and long-term maintenance, including dose interval extension. We also examined a development that reframes prevailing expectations; during 2026, both agents targeting the OX40–OX40L axis were withdrawn from development in atopic dermatitis, including one that was withdrawn after a malignancy signal. Together with earlier failures of alarmin blockade, this narrows the near-term pipeline and highlights the need for better use of existing therapies. Validated predictive biomarkers remain the principal unmet need.
SN - 1473-2300
SN - 0300-0605
ER -